FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313254907> ?p ?o ?g. }

• W4313254907 endingPage "257" @default.
• W4313254907 startingPage "248" @default.
• W4313254907 abstract "Prostate adenocarcinoma (CaP) is the leading cancer in men. After curative treatment, from 27% to 53% of patients will experience biochemical recurrence (BR). With the development of focal therapies, precise early identification of recurrence's sites is of utmost importance in order to deliver individualized treatment on positive lesions. The aim of this study was to assess the detection rate (DR) of 68Ga-PSMA-11 positron emission tomography/computed tomography (PET/CT) in selected patients with prostate cancer BR and recent negative 18F-choline PET/CT.We performed a retrospective analysis including all patients with CaP referred for BR with a negative 18F-choline PET/CT, and who underwent 68Ga-PSMA-11 PET/CT between October, 2018 and December, 2019. The overall DR of 68Ga-PSMA-11 PET/CT was calculated, and described according to BR characteristics especially PSA levels and velocity. Patients were followed up for at least 1 year. Patient management following 68Ga-PSMA-11 PET/CT and PSA levels evolution after treatment were also recorded.One hundred fifty-nine patients comprising 164 examinations were analyzed. The overall DR of 68Ga-PSMA-11 PET/CT for BR was 65.9% (95CI, 58.6-73.1). The DR was 52.5% (95CI, 39.9-65.0), 70.6% (95CI, 55.3-85.9), 70.4% (95CI, 53.1-87.6), and 78.6% (95CI, 66.2-91.0) for PSA levels between 0.2 and 0.49 ng/mL, 0.5 to 0.99 ng/mL, 1 to 1.99 ng/mL and PSA ≥ 2 ng/mL, respectively. The DR was 70.7% (95CI, 59.0-82.4) with a PSA doubling time (PSA-DT) ≤6 months and 65.2% (95CI, 55.5-74.9) with a PSA-DT >6 months. Around 3/4 of patients (75.9%) with a positive 68Ga-PSMA-11 PET/CT initiated treatment, including surgery (2.4%), stereotactic radiotherapy ± androgen deprivation therapy (ADT) (22%) or external conformational radiotherapy ± ADT (46.3%). Patient management changed in 43 cases (39.8%).Our study confirmed the ability of 68Ga-PSMA-11 PET/CT to detect occult biochemical recurrence, even in a selected population of CaP patients with negative 18F-choline PET/CT, even at low PSA levels." @default.
• W4313254907 created "2023-01-06" @default.
• W4313254907 creator A5004585311 @default.
• W4313254907 creator A5007574901 @default.
• W4313254907 creator A5024267268 @default.
• W4313254907 creator A5042994743 @default.
• W4313254907 creator A5045293970 @default.
• W4313254907 creator A5047909127 @default.
• W4313254907 creator A5048093562 @default.
• W4313254907 creator A5052526699 @default.
• W4313254907 creator A5070625960 @default.
• W4313254907 creator A5079196597 @default.
• W4313254907 creator A5091239799 @default.
• W4313254907 date "2023-04-01" @default.
• W4313254907 modified "2023-10-03" @default.
• W4313254907 title "PSMA-11 PET/CT for Detection of Recurrent Prostate Cancer in Patients With Negative Choline PET/CT" @default.
• W4313254907 cites W2021411036 @default.
• W4313254907 cites W2234163738 @default.
• W4313254907 cites W2612014481 @default.
• W4313254907 cites W2775321189 @default.
• W4313254907 cites W2801398567 @default.
• W4313254907 cites W2900624714 @default.
• W4313254907 cites W2905819979 @default.
• W4313254907 cites W2913023403 @default.
• W4313254907 cites W2915790793 @default.
• W4313254907 cites W2917217930 @default.
• W4313254907 cites W2924617625 @default.
• W4313254907 cites W2966792020 @default.
• W4313254907 cites W2980679062 @default.
• W4313254907 cites W2985011063 @default.
• W4313254907 cites W3005385207 @default.
• W4313254907 cites W3012827461 @default.
• W4313254907 cites W3013251573 @default.
• W4313254907 cites W3014715650 @default.
• W4313254907 cites W3042431606 @default.
• W4313254907 cites W3047110054 @default.
• W4313254907 cites W3092344805 @default.
• W4313254907 cites W3097158220 @default.
• W4313254907 cites W3116770432 @default.
• W4313254907 cites W3120675559 @default.
• W4313254907 cites W3136016043 @default.
• W4313254907 cites W3138539949 @default.
• W4313254907 doi "https://doi.org/10.1016/j.clgc.2022.12.007" @default.
• W4313254907 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36658064" @default.
• W4313254907 hasPublicationYear "2023" @default.
• W4313254907 type Work @default.
• W4313254907 citedByCount "0" @default.
• W4313254907 crossrefType "journal-article" @default.
• W4313254907 hasAuthorship W4313254907A5004585311 @default.
• W4313254907 hasAuthorship W4313254907A5007574901 @default.
• W4313254907 hasAuthorship W4313254907A5024267268 @default.
• W4313254907 hasAuthorship W4313254907A5042994743 @default.
• W4313254907 hasAuthorship W4313254907A5045293970 @default.
• W4313254907 hasAuthorship W4313254907A5047909127 @default.
• W4313254907 hasAuthorship W4313254907A5048093562 @default.
• W4313254907 hasAuthorship W4313254907A5052526699 @default.
• W4313254907 hasAuthorship W4313254907A5070625960 @default.
• W4313254907 hasAuthorship W4313254907A5079196597 @default.
• W4313254907 hasAuthorship W4313254907A5091239799 @default.
• W4313254907 hasConcept C121608353 @default.
• W4313254907 hasConcept C126322002 @default.
• W4313254907 hasConcept C126838900 @default.
• W4313254907 hasConcept C127077266 @default.
• W4313254907 hasConcept C2775842073 @default.
• W4313254907 hasConcept C2776235491 @default.
• W4313254907 hasConcept C2780192828 @default.
• W4313254907 hasConcept C2908761598 @default.
• W4313254907 hasConcept C2989005 @default.
• W4313254907 hasConcept C71924100 @default.
• W4313254907 hasConceptScore W4313254907C121608353 @default.
• W4313254907 hasConceptScore W4313254907C126322002 @default.
• W4313254907 hasConceptScore W4313254907C126838900 @default.
• W4313254907 hasConceptScore W4313254907C127077266 @default.
• W4313254907 hasConceptScore W4313254907C2775842073 @default.
• W4313254907 hasConceptScore W4313254907C2776235491 @default.
• W4313254907 hasConceptScore W4313254907C2780192828 @default.
• W4313254907 hasConceptScore W4313254907C2908761598 @default.
• W4313254907 hasConceptScore W4313254907C2989005 @default.
• W4313254907 hasConceptScore W4313254907C71924100 @default.
• W4313254907 hasIssue "2" @default.
• W4313254907 hasLocation W43132549071 @default.
• W4313254907 hasLocation W43132549072 @default.
• W4313254907 hasOpenAccess W4313254907 @default.
• W4313254907 hasPrimaryLocation W43132549071 @default.
• W4313254907 hasRelatedWork W2067891291 @default.
• W4313254907 hasRelatedWork W2077640666 @default.
• W4313254907 hasRelatedWork W2736007806 @default.
• W4313254907 hasRelatedWork W2906813322 @default.
• W4313254907 hasRelatedWork W2951337402 @default.
• W4313254907 hasRelatedWork W2976224709 @default.
• W4313254907 hasRelatedWork W3194480446 @default.
• W4313254907 hasRelatedWork W4281662033 @default.
• W4313254907 hasRelatedWork W4360954486 @default.
• W4313254907 hasRelatedWork W2623375208 @default.
• W4313254907 hasVolume "21" @default.
• W4313254907 isParatext "false" @default.
• W4313254907 isRetracted "false" @default.
• W4313254907 workType "article" @default.